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Background: Metacognitive dysfunction has been widely recognized as a feature of schizophrenia. As it is linked
with deficits in several aspects of daily life functioning, improvement of metacognition may lead to improvement in
functioning. Individual psychotherapy might be a useful form of treatment to improve metacognition in patients with
schizophrenia; multiple case reports and a pilot study show promising results. The present study aims to measure the
effectiveness of an individual, manual-based therapy (Metacognitive Reflection and Insight Therapy, MERIT) in improving
metacognition in patients with schizophrenia. We also want to examine if improvement in metacognitive abilities is
correlated with improvements in aspects of daily life functioning namely social functioning, experience of symptoms,
quality of life, depression, work readiness, insight and experience of stigma.
Methods/Design: MERIT is currently evaluated in a multicenter randomized controlled trial. Thirteen therapists in six
mental health institutions in the Netherlands participate in this study. Patients are randomly assigned to either MERIT or
the control condition: treatment as usual (TAU).
Discussion: If proven effective, MERIT can be a useful addition to the care for schizophrenia patients. The design brings
along some methodological difficulties, these issues are addressed in the discussion of this paper.
Trial registration: Current Controlled Trials: ISRCTN16659871.
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Metacognitive dysfunction has been widely recognized as
a feature of schizophrenia [1,2] and is linked with deficits
in daily life functioning [3-5]. Over the years, the construct
of metacognition has been defined in different ways. All
definitions describe a general capacity to think about
thinking [6]. Flavell [7] was one of the first to use the term.
In his view metacognition is closely related to ‘cognitive
monitoring’: the ability to observe one’s own cognitive
processes and to detect errors in these processes. Moritz
& Woodward [8] provide a more specific definition that* Correspondence: rozanne.donkersgoed@ggzfriesland.nl
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article, unless otherwise stated.targets dysfunctional thought processes in particular,
defining metacognition as ‘being aware of cognitive dis-
tortions’. Wells [9] includes thinking about feelings. He
also describes the important role of metacognition in
eliciting reactions triggered by these thoughts and feelings.
Based on the work of Semerari et al. on metacognition
[10], Lysaker et al. [11] propose to integrate different
definitions and propose a definition that involves four
fundamental aspects:
– Self-reflectivity: the ability to think about one’s own
thoughts and emotions;
– Understanding the other’s mind: the ability to think
about the thoughts and emotions of others;
– Decentration: the ability to understand that you are
not the center of the world and people’s lives
continue when you are not around;ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to define psychological problems and adequately
deal with them.
In this definition, metacognition refers to a spectrum
of activities, which involves thinking about thinking and
stretches from consideration of discrete psychological
phenomena (for example: recognizing an isolated thought)
to the synthesis of discrete perceptions into an integrated
representation of self and others [12]. Metacognitive
capacities “allow persons to form a detailed picture of
their own mental states, of the wishes and intentions
of the others, and of the inner and social cues that
trigger psychological pain, and thereby to cope with
challenges and solve complex social problems […]. In
the larger frame they make it possible for persons to
make sense of their dilemmas, to find meaning in life,
and to ultimately adapt to a changing environment”
[2]. In this way metacognitive dysfunction is more
than just a missing skill. It is the inability to make
complex sense of experience and integrate interper-
sonal information into a larger whole [12].
Several instruments have been developed to assess
elements of metacognition. Most of these instruments
capture more discrete aspects of the concept as it is
defined above, for example the Meta-Cognitions Ques-
tionnaire (MCQ) [13] which measures beliefs about
worries and intrusive thoughts and the Davos Assessment
of Cognitive Biases Scale (DACOBS) [14], measuring
cognitive biases. Semerari et al. [10] developed the
Metacognition Assessment Scale (MAS) based on the
four elements of metacognition. This instrument was
originally designed to measure metacognition in people
with personality disorders. Lysaker et al. [11] have short-
ened this instrument and adapted it for use with people
with psychotic disorders (MAS-A).
Metacognition is linked to aspects of daily life function
of patients with schizophrenia in several ways. Better
metacognitive mastery is linked to better social cognition
and more insight [2,15] and metacognition has been
found to mediate the impact of neurocognitive deficits
on social function, after controlling for symptoms [16].
Lower levels of metacognition correlate with less favorable
reports of the subjective experience of recovery [17] and
lower levels of functional competence [18]. In addition to
these daily life aspects, impaired metacognition has also
been associated with low quality of therapeutic alliance
[19] and more severe negative symptoms [11,20,21].
Moreover, lower levels of metacognition predict future
severity of negative symptoms, even after controlling
for concurrent levels of negative symptoms [22].
Based on the above, it is hypothesized that improved
metacognition will result in improved daily life functioning.
Metacognition might be a feasible target for treatment ofpeople with psychotic disorders. If an intervention would
be capable of improving metacognitive capacity, it would
enable persons with schizophrenia to achieve more com-
plex understanding of themselves and others and thus find
ways to actively direct their recovery process. Individual
psychotherapy might be a useful form of treatment to
improve metacognition. Several forms of psychotherapy
have successfully promoted metacognitive capacity in
persons with various mental disorders other than psychosis
[23], including work from a psychoanalytic [24] and a
cognitive frame of reference [25]. It has also been suggested
that some of these therapeutic procedures could be
modified for treatment of people with schizophrenia
[26]. If metacognition is conceptualized as a trait-like
capability that varies along a continuum from good to
impoverished, psychotherapy might provide a place to
practice such capacities in increasing degrees of complex-
ity, leading to enhancement of metacognitive capacity.
Manualized procedures for a metacognitive psychotherapy
for schizophrenia have been proposed [26] and multiple
detailed case reports and a pilot study have documented
the acceptability of the treatment and positive outcomes
[27-33]. The present paper presents the design of a random-
ized controlled multicenter trial that aims to measure the
effectiveness of the Metacognitive Reflection and Insight
Therapy (MERIT) in improving metacognition.
Research aims
Primary objective of this study is to investigate whether
Metacognitive Reflection and Insight Therapy improves
metacognitive abilities in people with schizophrenia. Sec-
ondary objective is to examine whether improvements in
metacognitive capacity lead to improvements in quality
of life, social functioning, depression, symptoms, stigma
sensitivity and work readiness. Neurocognition is adopted
in the assessment as well, as it may function as a mediator
between metacognition and functioning. A cost-effective-
ness analysis will be performed at the end of the study.
Methods/Design
The study is funded by Fonds NutsOhra, GGZ Drenthe,
GGZ Friesland and the Institute for Post master Psychology
in the Northern Netherlands (PPO). The study has been
approved by the medical ethical board of University Medical
Center Groningen, Groningen (number: METc2013.124,
date: november 2013), and is conducted in accordance
with the principles of the Declaration of Helsinki. Trial
number: ISRCTN16659871 (Current Controlled Trials).
Design
The study is designed as a multicenter randomized con-
trolled trial including an intervention group receiving
Metacognitive Reflection and Insight Therapy (MERIT)
and a control group receiving treatment as usual (TAU).
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Participants in the study are people with schizophrenia
or schizoaffective disorder and impaired metacognitive
abilities. A total of 120 participants will be included from
six mental health care institutions in the Netherlands.
Thirteen therapists who work in these facilities will be
trained to give the therapy.
Inclusion criteria are:
Impaired metacognitive skills, as measured by the
Metacognition Assessment Scale (MAS-A);
Diagnosis of schizophrenia or schizoaffective disorder,
according to DSM-IV-TR criteria;
Being able to give informed consent;
18 years or older;
No change in medication in the past thirty days.
Exclusion criteria are:
Acute psychosis (mean score of PANSS positive
symptoms >4);
Co-morbid neurological disorder;
Substance dependence (not substance abuse as
measured with the MINI Plus);
Impaired intellectual functioning (IQ <70)
Sample size calculation
Sample size was computed with a two-sided test using the
IBM SPSS Sample Power program (Biostat, M. Borenstein),
http://www.power-analysis.com/about_biostat.htm. The
effect size of MERIT is not known. We chose to adopt the
common convention in such instances, and set our effect
size at 0.5 [34]. This is based on the consideration that
should the effect size be lower, results would probably not
be clinically relevant [35,36]. In order to show medium
effect sizes (0.5) with an alpha of 0.05 and a power of 0.80,
a minimum of 48 subjects in both groups is required. This
means that there is an 80% likelihood that the study will
detect a statistically significant effect if such exists, and
allows us to conclude that the mean metacognition
score differs for MERIT versus TAU. Because this is a
time consuming trial with people with a severe mental
illness, we assume that the percentage of dropouts will
be 20%. This means that for every 120 subjects enrolled
in the study, 24 will be lost to follow-up or withdraw
informed consent and will be excluded from the analysis.
Therefore we will select 60 patients in the intervention
group and 60 patients in the control group including 12
extra participants in each group to compensate for the
anticipated missing data.
Procedure
Thirteen therapists in six Dutch mental health care insti-
tutions will select all patients in their caseload that meetthe inclusion criteria. They will answer four screening
questions concerning these patients’ metacognitive abilities
on a 10 point scale (see Section Screening for the screening
questions). The therapists approach the patients that score
below the cut-off of the screening and ask them if they are
interested in participation. The names of the interested
patients will be coded by the therapist. Out of these
coded names a random selection will be chosen by the
researchers to prevent selection bias. The selected coded
names will be transferred back to the therapists, who will
then provide the contact information of these patients
to the researcher and will inform the patients that an
assessor will approach them. The assessor will call the
patient and answer any questions the patient may have
about the study. Every participant has a two-week period
to consider participation. If the patient is still willing to
participate after this period, an assessor will make an
appointment for an intake to confirm that the patient
fulfills all of the study’s inclusion criteria. The intake will
take approximately 1,5 hours. Patients that are included
in the study will be randomly allocated to the treatment
condition (MERIT) or treatment as usual (TAU). The
randomization is conducted separately for each center
and procedures will start directly after the first participants
are included. Randomization will be done by a party
independent from the trial research team. Results of
the randomization process will be passed on to the
onsite therapists. Block randomization will be used to
ensure that the number of patients will be balanced over
condition. Assessors will be blind to the subject’s condi-
tion. Rater blinding will be verified after the assessment.
For therapists, it is of course not possible to be blind
for condition. After assignment to intervention or control
condition, the assessor plans a second appointment with
the patient for baseline assessment. A research assistant,
blind to treatment or control condition, who is not involved
in the patient's treatment, will carry out this assessment.
This assessment will take approximately 1.5 hours. There-
after, the individual treatment will start. Onsite clinical
psychologists that have partaken in the three-day MERIT
training will provide the intervention. Participants in
the control condition will receive treatment as usual
(TAU). After forty sessions of treatment or forty weeks
in the control condition, the assessment will be repeated
(post-treatment). Follow-up assessment will take place six
months after completion of the intervention.
Materials
A summary the design of the study and all materials is
provided in the table below (Table 1).
Metacognitive reflection and insight therapy (MERIT)
The experimental condition will receive the Metacognitive
Reflection & Insight Therapy [based on 26]. This manual-
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elements of metacognition. The treatment protocol is not
a step-by-step program, but is target-driven. The therapist
tries to elicit a narrative; a personal story of the patient.
In this personal narrative, the therapist looks for targets;
signs of metacognition. Is the patient aware of his
thoughts? Can he reflect on those thoughts and on the
thoughts of others? The levels of MAS-A are used here
to classify the different levels of metacognitive functioning.
The therapist adjusts his interventions according to the
level of metacognition of the patient and stimulates the
patient to perform ever more complex metacognitive
tasks. The therapy will consist of 40 times 45 minutes
of individual therapy sessions. The treatment protocol
has been translated into Dutch by the research team.
Every participating therapist will follow a three-day
training in the therapy provided by PL, the first author
of the therapy manual. The most important aspects of the
therapy are summarized in the Therapist Metacognitive
Adherence Scale (T-MAS, see Table 2). The eight core
items of the T-MAS are explained in detail in the protocol
and the therapists will practice these elements in the
training. The therapist has to give him/herself a score
on a ten-point scale on the items of the T-MAS after
every therapy session. In this way the therapist can
monitor his/her own adherence to the aspects of theTable 1 Study design
Instrument: Selection Intake Assessment to condi




















MERIT therapy or controltherapy. Transcripts of sessions will be selected at random
and will be scored by independent assessors with the
T-MAS, to monitor if the therapist follows the elements
of the therapy correctly. Every other week each therapist
will receive supervision by the developer of the therapy,
PL, using Skype. In these sessions the adherence to the
therapy elements and the T-MAS scores will be discussed
and the therapists receive supervision on how they
conduct the therapy.
Screening
On-site therapists will screen all patients in their caseload
that meet the inclusion criteria; they will answer four
screening questions concerning each of these patients’
metacognitive abilities:
– To what extent is the patient able to think about
his/her own thoughts?
– To what extent is the patient able to explain his/her
thoughts and feelings in an adequate manner?
– To what extent is the patient able to explain the
thoughts and feelings of others in an adequate manner?
– To what extent is the patient able to use his/her
understanding of his/her own thoughts and feelings
and the thoughts and feelings of others to react



















Table 2 The therapist metacognitive adherence scale
Openness to the patient’s agenda at the session outset and throughout the session. 1 2 3 4 5
Offer of the therapist’s thoughts/perceptions regarding the patient’s behavior in the session. 1 2 3 4 5
Details of a narrative episode are elicited. 1 2 3 4 5
A psychological problem or dilemma is framed as something to be discussed. 1 2 3 4 5
Reflection on the interpersonal processes during the session is elicited. 1 2 3 4 5
Reflection on progress/course of the session is elicited at various times during the session or at session’s end. 1 2 3 4 5
The patient is stimulated to engage in metacognitive acts with interventions that are appropriate to patient’s
capacity for self-reflectivity and/or awareness of the mind of the other.
1 2 3 4 5
The patient is stimulated to engage in metacognitive acts with interventions that are appropriate to patients’
capacity for metacognitive mastery.
1 2 3 4 5
Key: 1. Absent; 2. Intermittent moments in which basic competency is present; 3. Fully adequate or competent throughout; 4. Fully adequate with some periods
of exceptional performance; 5. Consistently exceptional performance.
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scale, 10 meaning excellent, 0 very poor. They select all
the patients that score below 6 on two or more of the four
questions, who will be approached for participation.
Intake
Diagnosis M.I.N.I Plus Interview [37]. This structured
interview is used to confirm a diagnosis of schizophrenia
or schizoaffective disorder. It is designed to detect Axis I
diagnoses of the DSM IV-TR. The interview is divided
into 26 sections; each section concerns a diagnostic
category. At the end of every category the interviewer
can determine whether the patient fulfills the diagnostic
criteria for the diagnosis of the particular section.
Metacognition Indiana Psychiatric Illness Interview [38].
This interview, which consists of five open questions, was
developed with the goal of eliciting the life story and
illness history of the patient. The MAS-A can be scored
on the resulting transcript.
Metacognition Assessment Scale [10,11]. The MAS-A
consists of four scales. The cutoff points for each scale:
Selfreflectivity: below 5.5, Understanding the other’s
mind: below 4.5, Decentration: below 2, Mastery: below
4.5. When the patient gets a score below cut off on three
or more scales, metacognitive deficits are prominent and
the patient meets the inclusion criteria.
Symptoms Positive and Negative Syndrome Scale [39]. This
structured interview consists of thirty items, each ranging
from one to seven. The items fall into three subscales: posi-
tive symptoms, negative symptoms and general symptoms.
Assessment
Metacognition Beck Cognitive Insight Scale (BCIS) [40].
This self-report questionnaire evaluates the reflectiveness
and overconfidence in the interpretation of experiences of
the patient. It consists of fifteen items, six items representthe self-certainty subscale, nine items represent the self-
reflectiveness subscale.
Faux Pas Task [41]. This task consists of ten stories,
describing interpersonal, everyday situations. Some of these
stories contain a ‘faux pas’: a speaker in the story says
something without considering if it is something that
the listener might not want to hear. The patient has to
detect these mistakes.
Empathic Accuracy Task (EAT) [42]. This task consists
of ten videos of people who tell a personal story. The
participant has to rate the mood of the person in the
video continuously on a 9 point scale.
Interpersonal Reactivity Index (IRI) [43]. This question-
naire exists of 28 statements. The participant has to indicate
whether the statement applies to him/her on a six point
scale.
Depression The Quick Inventory of Depressive Symptom-
atology Self Report (QIDS-SR) [44]. This self-report ques-
tionnaire consist of sixteen items, measuring depressive
symptoms according to the DSM-IV in the week before
assessment.
Stigma The Internalized Stigma of Mental Illness Scale
(ISMI) [45]. This is a self-rating questionnaire with 29
questions designed to measure the subjective experience of
stigma. It consists of five subscales: Stereotype Endorse-
ment, Perceived Discrimination, Social Withdrawal, Stigma
Resistance and Alienation.
Quality of life Self-rating Manchester Short Assessment of
Quality of Life (MANSA) [46]. This questionnaire consists
of four objective questions and twelve subjective questions.
These subjective questions assess satisfaction with life
as a whole, job, financial situation, number and quality
of friendships, leisure activities, accommodation, personal
safety, people that the individual lives with, sex life, rela-
tionship with family, physical health and mental health. It
is a self-report, 16 Likert-scale item measure.
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view investigates the way in which the patient spends his/
her time and makes a detailed account of his/hers: em-
ployment, education and training, voluntary work, leisure
activities, hobbies, child care, housework and chores.
Work readiness Work Readiness Questionnaire (WoRQ)
[48]. This questionnaire is filled in by the therapist of the
client and has seven items designed to capture the
patient's readiness to work as reflected by current capacity
to initiate and maintain a useful activity. The items are
rated to provide graded measurements, i.e., “strongly
agree”, “agree”, “disagree” or “strongly disagree”. Next
to these seven items it contains a final dichotomous
work readiness judgment.
Neurocognition Nederlandse Leestest voor Volwassenen
(NLV) [49]. The NLV tests the pronunciation of irregu-
larly spelled words and is used to determine premorbid
intelligence.
Trailmaking test A&B (TMT) [50]. The TMT provides
information on visual search, scanning, mental flexibility
speed of processing and executive functions. It is part
of the Halstead–Reitan Battery [50]. The TMT consists
of two parts. Part A requires an individual to draw lines
sequentially connecting 25 encircled numbers distributed
on a sheet of paper. Task requirements are similar for Part
B except the person must alternate between numbers and
letters (e.g., 1, A, 2, B, 3, C, etc.). The score on each part
represents the amount of time required to complete the
task [51].
Digit Symbol Test (part of the Wechsler Adult Intel-
ligence Scale [52]). This test evaluates the recognition and
recoding of visual information. The test consists of several
rows of paired boxes with a digit in the top box and
an empty space in the box below. At the top of the
page is shown which symbols are paired to the digits.
The participant has to fill in as many symbols in the
empty boxes within 90 seconds.
Cost-effectiveness EuroQol (EQ-5D) [53]. This question-
naire contains five scales: self care, mobility, usual activities,
pain/discomfort and anxiety/depression. The participant
has to rate his/her health as it is on the day of the inter-
view, using five levels: “no problem” “slight problems”
“moderate problems”, “severe problems”, “unable”/”extreme
problems” [54].
TiC-P [55]. This is a questionnaire. The first part consists
of medical resource items, including: contacts within the
mental healthcare sector, self-help groups, contacts with
general healthcare providers, and the use of medication.
The patient has to indicate whether he/she makes use of
these items and if yes, how many times. Depending on the
relevance for the target population, the questionnaire allowsadding or leaving out specific items of resource utilization.
Part two consist of the Short Form-Health and Labour
Questionnaire (SF-HLQ) an instrument that collects data
on productivity losses due to health problems. This part
measures absence from work and reduced.
Statistical analysis
Descriptive statistics
Descriptive statistics will be provided for all normally
distributed variables in the form of mean scores (and
standard deviations) before and after the intervention on
each of the assessment instruments. Descriptive statistics
of variables that are not normally distributed will be rep-
resented as median scores and ranges.
Analysis
Differences in scores on every dependent variable are
measured before and after the intervention and six
months after the end of intervention. The significance of
possible differences will be tested using logistic multilevel-
ing modeling [56] with the subject and assessment time as
levels and condition as independent variable. A model
will be constructed for every dependent variable using the
program MlwiN [57]. Dummy variables will be constructed
for every level and the statistical significance of the
regression-effects will be tested using the T-test. The
dummy-variables and their interactions will be added
to the model as fixed effects.
Discussion
With this multicenter randomized controlled trial, we
intend to investigate the effectiveness of a manual-based
psychotherapy aimed at improving metacognition and
daily life functioning of patients with schizophrenia.
Metacognition is a complex, multi-dimensional concept,
involving four main aspects: self reflection, understanding
the mind of the other, decentration and mastery. It not
only refers to the ability to detect and consider discrete
psychological phenomena (for example: recognizing a
thought), but also to the ability to integrate these phe-
nomena into an integrated, complex representation of self
and others [12]. MERIT tries to enhance these synthetic
metacognitive processes through constant reflection in the
interpersonal relationship. In this way, the patient learns
to reflect on him/herself in ever more complex ways. We
hope this will result in structural changes in metacognitive
processes in patients with schizophrenia, and hope this in
turn will lead to structural, lasting improvements of daily
life functioning of the patient. This design brings along
some methodological difficulties, especially the risk of
drop-out over time. We hope to account for this by in-
cluding 20% extra patients in the trial to ensure statistical
power will be maintained despite patient attrition.
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the Netherlands target first-episode patients within five
years after the first psychotic episode. Care for chronic
patients usually focuses on support and structure instead
of recovery. MERIT can be used with patients who are
chronically mentally ill, and case studies show promising
results. If proven effective, this therapy might be a useful
addition to the care for chronic schizophrenia patients.
Furthermore, some patients benefit less from usual inter-
ventions such as psycho-education and cognitive behavioral
therapy. It could be hypothesized that these patients are
not able to form complex representations of self and others,
which makes it difficult to engage in therapy. Improving
metacognition might prove a necessary step for these
patients to benefit from other interventions and enhance
daily functioning.
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